Full Text View
Tabular View
Study Results
Related Studies
Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age
This study has been completed.
Study NCT00244621   Information provided by AstraZeneca
First Received: October 25, 2005   Last Updated: August 7, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hypertension
More general conditions related to this trial
Cardiovascular Diseases
Vascular Diseases
Interventions listed in this trial
candesartan cilexetil (Atacand)
Additional drug interventions recognized in this trial
Candesartan
Candesartan cilexetil
More general drug interventions related to this trial
Angiotensin II Type 1 Receptor Blockers
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services